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Effect of manipulating serum phosphorus
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Phosphorus directly controls parathyroid hormone (PTH)
synthesis and secretion. Serum levels of the novel
phosphate-regulating hormone, fibroblast growth factor 23
(FGF23), are positively correlated with hyperphosphatemia in
patients with chronic renal insufficiency (CRI). We proposed
that changes in serum PTH and FGF23 levels might be
associated with changes in serum phosphorus levels caused
by the phosphate binder sevelamer hydrochloride
(sevelamer, i.e. crosslinked poly[allylamine hydrochloride]).
Rats were fed a diet containing adenine for 4 weeks to
establish CRI. Animals were then offered either a normal diet
or a diet containing 1 or 3% sevelamer for 8 weeks
continuously, or intermittently with sevelamer diet or a
normal diet offered for alternating 2-week periods. Changes
in the serum levels of phosphorus, calcium, PTH, FGF23, and
1a,25-dihydroxyvitamin D3 (1,25(OH)2D3) were monitored
over time. Adenine-treated rats developed severe CRI, with
markedly elevated serum levels of phosphorus, PTH and
FGF23, and reduced levels of serum 1,25(OH)2D3. Continuous
treatment with sevelamer suppressed these increases
throughout the study period. Serum phosphorus, PTH, and
FGF23 levels decreased rapidly when sevelamer treatments
commenced and recovered rapidly once they were
discontinued. However, the changes in serum FGF23 levels
began after the onset of changes in serum phosphorus and
PTH levels. In conclusion, circulating PTH, and FGF23 levels
can be promptly manipulated through the control of serum
phosphorus levels. Moreover, phosphate-binder treatment
can effectively inhibit the elevation of serum FGF23 levels, as
well as PTH levels, under conditions of CRI.
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Hyperphosphatemia is a major complication in hemodialysis
patients and plays a key role in the pathogenesis of secondary
hyperparathyroidism (2HPT).1–3 It is now widely accepted
that phosphate directly stimulates parathyroid hormone
(PTH) secretion and synthesis, as well as parathyroid cell
proliferation, independently of calcium and 1a,25-dihydroxy-
vitamin D3 (1,25(OH)2D3). Conversely, restricting phosphate
by means of a low phosphorus diet or phosphate-binder
treatment can reverse hyperparathyroidism.
Fibroblast growth factor 23 (FGF23) was recently
identified as a causative factor in phosphate-wasting
disorders, such as tumor-induced osteomalacia, autosomal
dominant hypophosphatemic rickets and X-linked hypophos-
phatemic rickets.4 Marked elevations of serum FGF23 levels
have been positively correlated with serum levels of
phosphorus, calcium and PTH in patients with end-stage
renal disease.5–8 Interestingly, total parathyroidectomy (PTx)
reduced serum phosphorus levels and simultaneously de-
creased serum FGF23 levels in patients on dialysis.8 In healthy
subjects, serum FGF23 levels decreased on a low phosphorus
diet and increased with oral phosphorus load,9 although an
alternative study reported that FGF23 levels were not affected
by oral phosphorus deprivation or loading.5 In an animal
study, a high phosphorus diet increased serum FGF23 levels
in 5/6 nephrectomized rats.10 On the other hand, the
administration of recombinant FGF23 slightly decreased
serum PTH levels in normal mice and reduced serum
phosphorus and 1,25(OH)2D3 levels in rats that underwent
PTx.11 Conversely, the administration of 1,25(OH)2D3
increased serum FGF23 levels in mice11 and thyroparathy-
roidectomized rats without correlation with serum phos-
phorus levels.10 Thus, it remains unclear whether phos-
phorus, calcium, PTH, 1,25(OH)2D3 or an alternative factor
is directly responsible for the marked elevation of circulating
FGF23 levels under chronic renal insufficiency (CRI)
conditions.
Sevelamer hydrochloride (sevelamer, crosslinked poly-
[allylamine hydrochloride]) is a metal-free phosphate-binding
polymer that is marketed for the treatment of hyperphosphat-
emia in patients on dialysis. Previously, we demonstrated
beneficial protective effects of sevelamer on parathyroid cell
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proliferation,12 parathyroid hyperplasia,13 renal functional
deterioration,14 and high-turnover bone lesions15 in rats with
progressive CRI, in addition to its lowering effects on serum
phosphorus and PTH levels and on urinary phosphorus
excretion in normal rats16 and rats with CRI.12–15
Excess dietary adenine is converted to 2,8-dihydroxy-
adenine, which is significantly less soluble in water, and
impairs renal function by forming intratubular and inter-
stitial precipitates of acicular crystals.17,18 Severe CRI,
accompanied by hyperphosphatemia and 2HPT, is seen in
adenine-treated rats.15 In the present study, we examined
how serum PTH and FGF23 levels were affected by
manipulating serum phosphorus levels through the inter-
mittent administration of sevelamer in adenine-treated rats.
RESULTS
Body weight and food intake volume
Body weight gain was reduced in the adenine-treated rats
compared to that in the normal control group (Figure 1a).
The sevelamer treatments did not significantly affect body
weight during the study, although a slight increase was
observed in the 3% sevelamer continuous-treatment group.
The mean food intake volumes in g/day were as follows:
25.470.47 for the normal control group; 12.170.63 for the
disease control group; 13.370.46 for the 1% sevelamer
continuous-treatment group; 15.270.61 for the 3% sevelamer
continuous-treatment group; 12.670.50 for the 1% sevelamer
intermittent-treatment group; and 14.370.69 for the 3%
sevelamer intermittent-treatment group.
Blood urea nitrogen and serum creatinine levels
The blood urea nitrogen (BUN) and serum creatinine levels
increased rapidly during the 4 weeks of adenine treatment
(days 28 to 1; Figure 1b and c). After the end of the
adenine treatment period, the BUN, and serum creatinine
levels remained high, although they began to decrease
gradually towards the end of the study. The sevelamer
treatments had no significant effect on the BUN and serum
creatinine levels during the study, regardless of whether it was
given continuously or intermittently.
Serum phosphorus levels
In the disease control group, the serum phosphorus levels
increased rapidly during the adenine treatment (days 28 to
1), reached a maximum at the end of this period and
showed a slight decrease towards the end of the study
(Figure 2). At 1 day after switching from the adenine diet to
the 1 or 3% sevelamer diets (day 1), the serum phosphorus
levels decreased rapidly to around the normal control levels.
In the 3% sevelamer groups, further decreases in serum
phosphorus levels were observed both 3 and 7 days after the
treatment commenced (days 3 and 7), while in the 1%
sevelamer groups, normal levels were maintained. Serum
phosphorus levels in the 1% sevelamer continuous-treatment
group remained similar to those of the normal control group,
while in the 3% sevelamer continuous group, the levels were
below those in the normal controls until the end of the study
(Figure 2a). In the 3% sevelamer intermittent-treatment
group, the serum phosphorus levels rapidly returned to
normal control levels on day 15 (i.e., 1 day after the normal
diet started), increased above the disease control levels on day
17 (i.e., 3 days after the normal diet started) and then
gradually decreased (Figure 2b). The second cycle of
treatment with sevelamer (days 28–42) suppressed serum
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Figure 1 | Effects of sevelamer on (a) body weight, (b) blood urea
nitrogen (BUN), and (c) serum creatinine levels. Normal control,
open circle; disease control, filled circle; 1% sevelamer continuous
treatment, open triangle; 3% sevelamer continuous treatment, open
square; 1% sevelamer intermittent treatment, filled triangle; and 3%
sevelamer intermittent treatment, filled square. Statistically signifi-
cant differences (Po0.001) between the normal and disease control
groups were observed in body weight from days 21 to 56 and in
both the BUN and the serum creatinine levels from days 15 to 56
(not indicated in the figures). The sevelamer treatments had no
statistically significant effects.
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phosphorus levels, whereas discontinuation of the treatment
(day 42) caused them to begin to rise again.
Serum calcium levels
Slight hypercalcemia followed by slight hypocalcemia was
observed in the disease control group compared to the
normal control group (Figure 3). Serum calcium levels
rapidly increased within 3 days of the start of the 1 and 3%
sevelamer treatments, and the continuous-treatment groups
maintained relatively high levels throughout the study
(Figure 3a). Three days after switching from the sevelamer
diet to the normal diet, marked reductions in serum calcium
levels were observed in the intermittent-treatment groups
(days 17 and 45) (Figure 3b).
Serum PTH levels
In the disease control group, serum PTH levels rose
progressively and dramatically throughout the study (Fig-
ure 4). By contrast, once the 1% sevelamer treatments had
commenced, the serum PTH levels began to decrease
gradually, while the 3% sevelamer treatments caused the
serum PTH levels to decrease rapidly to around the normal
control levels just 1 day after they commenced (day 1), and
caused further decreases below the normal control levels until
day 13. The 1 and 3% sevelamer continuous treatments
continued to reduce serum PTH levels dose-dependently
until the end of the study (Figure 4a). In particular, the 3%
sevelamer continuous treatment kept the serum PTH levels
below the normal control levels during the early part of the
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Figure 2 | Effects of (a) continuous treatment and (b) intermittent
treatment with sevelamer on serum phosphorus levels. Normal
control, open circle; disease control, open triangle; 1% sevelamer
treatment, filled triangle; and 3% sevelamer treatment, filled square.
The time schedule for the treatment with sevelamer is indicated
along the bottom of each graph. The groups and experimental days
on which statistically significant differences were observed are
indicated in the table below. #Po0.05, ##Po0.01, ###Po0.001 vs the
normal control group. *Po0.05, **Po0.01, ***Po0.001 vs the disease
control group.
Exp. Day -29 -15 -1 1 3 7 13 15 17 21 27 31 35 42 45 49 56
Disease control # ### ### ### ### ### ## ## ## ## ### ## ### ### # ## #
1% continuous *** *** *** *** * * ** *** *** *** ***
3% continuous *** *** *** *** *** *** *** *** *** *** *** * **
1% Intermittent *** *** *** *** * *** *** ***
3% Intermittent *** *** *** *** * *** *** ***
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Figure 3 | Effects of (a) continuous treatment and (b) intermittent
treatment with sevelamer on serum calcium levels. Normal
control, open circle; disease control, open triangle; 1% sevelamer
treatment, filled triangle; and 3% sevelamer treatment, filled square.
The time schedule for the treatment with sevelamer is indicated
along the bottom of each graph. The groups and experimental days
on which statistically significant differences were observed are
indicated in the table below. #Po0.05, ###Po0.001 vs the normal
control group. *Po0.05, **Po0.01, ***Po0.001 vs the disease control
group.
Exp. Day 3 7 13 15 17 21 27 31 35 42 45 49 56
Disease control ### # #
1% continuous * * ** *** *
3% continuous * * *** *** ** *** *** *** *** *** ** *** *
1% Intermittent ** **
3% Intermittent * *** * * *** ***
#
Kidney International (2006) 69, 531–537 533
N Nagano et al.: Control of PTH and FGF23 by phosphorus o r i g i n a l a r t i c l e
study. At 1 day after switching from the sevelamer diet to the
normal diet, the serum PTH levels rapidly and markedly
increased, especially in the 3% sevelamer intermittent-
treatment group (day 15) (Figure 4b). The second inter-
mittent treatments of sevelamer (days 28–42) decreased the
serum PTH levels, and discontinuation of these treatments
(day 42) caused the serum PTH levels to begin to rise again;
the magnitude of the changes was greater in the 3%
sevelamer intermittent-treatment group than in the 1%
group.
Serum FGF23 levels
In the disease control group, the serum FGF23 levels
progressively and dramatically increased, reaching a max-
imum on day 15 and then decreasing gradually (Figure 5).
Even the high dose (3%) sevelamer treatments did not affect
serum FGF23 levels 1 day after they were initiated (day 1),
and the levels decreased gradually between days 3 and 13. In
the 1 and 3% sevelamer continuous-treatment groups, serum
FGF23 levels continued to decrease dose-dependently until
the end of the study (Figure 5a). In the high dose (3%)
sevelamer intermittent-treatment group, there was no effect
on the serum FGF23 levels 1 day after switching from the
sevelamer diet to the normal diet on day 15, but it began to
rise from day 17 onwards (Figure 5b). The second treatments
with sevelamer (days 28–42) decreased the serum FGF23
levels and discontinuation of treatments (day 42) caused the
levels to begin to rise again; the magnitude of the changes was
greater in the 3% sevelamer intermittent-treatment group
than in the 1% group.
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Figure 4 | Effects of (a) continuous treatment and (b) intermittent
treatment with sevelamer on serum parathyroid hormone (PTH)
levels. Normal control, open circle; disease control, open triangle; 1%
sevelamer treatment, filled triangle; and 3% sevelamer treatment,
filled square. The time schedule for the treatment with sevelamer is
indicated along the bottom of each graph. The groups and
experimental days on which statistically significant differences were
observed are indicated in the table below. ##Po0.01, ###Po0.001 vs
the normal control group. **Po0.01, ***Po0.001 vs the disease
control group.
Exp. Day -15 -1 1 3 7 13 15 17 21 27 31 35 42 45 49 56
Disease control ### ### ### ### ### ### ### ### ## ### ### ### ### ### ### ##
1% continuous *** *** *** *** ** ** *** *** *** *** *** ***
3% continuous *** *** *** *** *** *** *** *** *** *** *** *** *** **
1% Intermittent *** *** *** *** ** ** **
3% Intermittent *** *** *** *** *** *** *** *** ** ***
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Figure 5 | Effects of (a) continuous treatment and (b) intermittent
treatment with sevelamer on serum fibroblast growth factor 23
(FGF23) levels. Normal control, open circle; disease control, open
triangle; 1% sevelamer treatment, filled triangle; and 3% sevelamer
treatment, filled square. The time schedule for the treatment with
sevelamer is indicated along the bottom of each graph. The groups
and experimental days on which statistically significant differences
were observed are indicated in the table below. ##Po0.01,
###Po0.001 vs the normal control group. **Po0.01, ***Po0.001 vs
the disease control group.
Exp.Day -15 -1 1 3 7 13 15 17 21 27 31 35 42 45 49 56
Disease control ### ### ### ### ### ### ### ### ## ### ### ### ### ### ### ##
1%c ontinuous ** *** *** *** *** ** ** *** *** *** *** *** ***
3% continuous *** *** *** *** *** *** *** *** *** *** *** *** *** **
1% Intermittent ** *** *** *** *** ** ** **
3% Intermittent *** *** *** *** *** *** *** *** ** ***
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Serum 1,25(OH)2D3 levels
During the adenine treatment (days 28 to 1), the serum
1,25(OH)2D3 levels decreased markedly, reaching values close
to zero, and then increased slightly as the study progressed
(Figure 6). The sevelamer treatments had no significant effect
on serum 1,25(OH)2D3 levels during the study.
DISCUSSION
Rats fed with adenine were chosen as an animal model for
CRI in this study because it is simple to produce and shows
relatively stable, long-lasting, and severe uremia, with
hyperphosphatemia and 2HPT, even after the discontinua-
tion of adenine feeding.15 Intermittent sevelamer treatments
were used to manipulate the circulating phosphorus levels
dynamically, and the concomitant changes in serum PTH and
FGF23 levels were monitored.
Prior to this study, a lag period between the start of
sevelamer treatment and the onset of the reduction of serum
phosphorus levels was predicted due to the mobilization of
phosphate from the bones and intracellular pools. However,
serum phosphorus levels were found to decrease 1 day after
the start of the sevelamer treatments. Conversely, a rise in the
serum phosphorus levels was observed 1 day after the
sevelamer treatments were discontinued and they returned to
their original levels within 3 days. At 3 days after the
discontinuation of the high dose (3%) sevelamer treatment, a
rebound phenomenon (i.e., marked hyperphosphatemia) was
observed, particularly on day 17. This suggested that an
intestinal phosphate absorption system, probably comprised
of Na/Pi cotransporter type IIb (Na/Pi IIb), might have been
upregulated during the phosphorus restriction caused by
2-week sevelamer treatment. It is of some interest that
phosphate depletion might still result in the upregulation of
Na/Pi IIb even under conditions of very severe CRI.
The sevelamer treatments increased the serum calcium
levels dose-dependently. The increased serum calcium levels
are partly dependent on the reduction of serum phosphorus
levels induced by sevelamer treatment (i.e., a counter-ion
effect). In addition to this mechanism, we reported
previously that sevelamer treatment decreased fecal calcium
excretion and increased intestinal calcium absorption in a
balance study with normal rats.19 Thus, it is also likely that
intestinal phosphate binding by sevelamer might increase the
concentration of free calcium ions, resulting in increased
intestinal calcium absorption. Furthermore, the marked
reduction in serum PTH levels by sevelamer might decrease
the bone capacity to buffer an intestinal extra calcium load
and facilitate the elevation of serum calcium levels.
Interestingly, serum PTH levels continued to rise progres-
sively during the study in adenine-treated rats receiving the
normal diet (disease control group), despite stable or only
minor decreases in levels of serum creatinine, phosphorus
and calcium levels and the minor increase in 1,25(OH)2D3
levels. This indicated a progressive development of parathy-
roid hyperfunction, independent of renal function, calcium,
phosphorus and 1,25(OH)2D3 levels, suggesting that long-
lasting uremic conditions per se can promote 2HPT.
The elevated serum PTH levels rapidly decreased when the
sevelamer treatments commenced, and returned to their
original levels soon after discontinuation of the treatments.
Along with the rapid recovery of serum phosphorus levels
after the discontinuation of the sevelamer treatments, these
findings support that clinical treatment with a phosphate
binder should not be discontinued abruptly. The time course
of the changes in serum PTH levels was similar to that for
serum phosphorus levels. An in vitro study demonstrated
previously that elevated phosphate concentrations in the
culture media increased PTH secretion from the rat
parathyroid gland within 3 h.20 Another in vivo study using
normal dogs showed that continuous intravenous infusion of
phosphate increased serum PTH levels within 90 min under
the serum calcium clamp conditions.21 Although we were
unable to examine the hourly changes in serum parameters,
the onset of the changes in serum PTH levels seemed likely to
follow those of the serum phosphorus levels. These observa-
tions also support a direct and acute effect of phosphate on
PTH secretion in vivo, although part of the serum PTH
changes could be explained by the serum calcium changes
induced by the sevelamer treatments.
A marked elevation in serum FGF23 levels was observed in
the adenine-treated rats, which was consistent with previous
reports of patients and animals with CRI.5–8,10 FGF23 mRNA
is present in many tissues, including the thymus, brain, bone,
thyroid/parathyroid gland and heart.22–24 According to a
recent study,25 abundant FGF23 expression in the bone seems
to be conclusive, but expressions in some other organs are
still controversial. In addition, it remains unclear as to which
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Figure 6 | Effects of sevelamer on serum 1,25(OH)2D3 levels.
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statistically significant effects.
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of these organs makes the largest contribution to the
significantly elevated circulating FGF23 levels in CRI.
Furthermore, the presence of FGF23 in urine has suggested
that increased FGF23 levels in CRI are partly due to a
decreased clearance of FGF23 by the kidney.5 However, the
present result that the intermittent sevelamer treatment
drastically changed serum FGF23 levels without affecting
renal function clearly indicates that declining renal clearance
of FGF23 is not solely responsible for its upregulation. This
result may also suggest a hypothesis that the FGF23 response
is physiologically relevant rather than a nonimportant
consequence of CRI. In addition to the renal tubular lesions
in adenine-treated rats, it is considered that marked elevation
of serum FGF23 levels partly contributes to the depletion of
serum 1,25(OH)2D3 levels. At present, with the exception of
the potent downregulation of renal 25-hydroxyvitamin D3-1
alpha-hydroxylase and Na/Pi IIa in physiological conditions,
the functional significance of the elevated serum FGF23 levels
under CRI conditions remains unclear. However, the present
study is the first to show that phosphate-binder treatment
can effectively inhibit the elevation of serum FGF23 levels, as
well as PTH levels, under CRI conditions.
Similar to the influences on serum PTH levels, initiating
and discontinuing the sevelamer treatments decreased and
increased the serum FGF23 levels. However, the onset of the
changes in serum FGF23 levels showed a lag period (at least
1–3 days), and followed the changes in serum phosphorus
and PTH levels; serum FGF23 levels were not altered 1 day
after the sevelamer treatments began or ended. Similar
observations were reported in healthy human subjects, whose
serum FGF23 levels decreased on a low phosphorus diet and
then increased with an increased oral intake; it took 5–7 days
to detect any significant changes in these individuals.9 In
addition, a high phosphorus diet was shown to enhance, and
a low phosphorus diet to inhibit, the elevation of serum
FGF23 levels in 5/6 nephrectomized rats, although this result
was obtained after 4 weeks of the dietary treatment.10 Taken
together, these findings suggest that serum FGF23 is
predominantly regulated by phosphorus, although it is
unclear why a lag period occurs. The regulatory mechanisms
for FGF23 production and/or secretion should be clarified.
It is possible that serum PTH levels might determine
circulating FGF23 levels, because the PTx can reduce FGF23
levels in patients on dialysis.8 However, despite complete
surgical ablation of the parathyroid glands, the magnitude of
the changes in serum FGF23 levels was relatively small and
the serum phosphorus levels simultaneously decreased in this
report. Further studies using PTx rats should be conducted in
order to exclude the PTH-dependent regulation of FGF23.
The administration of FGF23 lowers serum 1,25(OH)2D3
levels, and 1,25(OH)2D3 reciprocally increases FGF23 levels
in mice11 and rats in the absence of the parathyroid gland,10
suggesting that 1,25(OH)2D3, as well as phosphate, regulates
circulating FGF23 levels. However, the sevelamer treatment
decreased serum FGF23 levels without influencing serum
1,25(OH)2D3 levels, indicating that the changes in serum
FGF23 levels observed in this study were independent of
1,25(OH)2D3. Another possibility remained that serum
calcium might have been involved in the regulation and
determination of circulating FGF23 levels in this study. Thus,
further research will be necessary to determine which factor is
directly responsible for the significantly elevated circulating
FGF23 levels under CRI conditions. However, the present
study suggests that serum phosphorus levels predominantly
determine the circulating FGF23 levels.
CONCLUSION
Elevated circulating PTH and FGF23 levels were lowered
rapidly by the initiation of phosphate-binder treatment, even
under severe 2HPT conditions. However, after discontinua-
tion of the phosphate-binder treatment, the PTH and FGF23
levels recovered promptly. This is the first report showing
that phosphate-binder treatment can effectively inhibit the
elevation of serum FGF23 levels, as well as PTH levels, under
CRI conditions.
MATERIALS AND METHODS
Experimental protocol
The experimental protocol shown in Table 1 was approved by the
Experimental Animal Ethical Committee of Kirin Brewery Co. Ltd.
Male Sprague–Dawley rats (8 weeks old) were purchased from
Charles River Japan (Tokyo, Japan) and fed a standard powder diet
containing 1.09% phosphorus, 1.17% calcium, 24.9% crude protein
and 2.4 IU/g vitamin D3 (CE-2, CLEA Japan, Tokyo, Japan). The rats
were kept singly in cages and allowed free access to food and water.
After an acclimatization period of 10 days, a blood sample was
collected from the tail artery of each animal to measure serum levels
of phosphorus, calcium, creatinine, BUN, PTH, FGF23, and
1,25(OH)2D3 on experimental day 29. The rats were divided into
Table 1 | Experimental protocol
1% sevelamer
3% sevelamer
Normal control Normal diet Normal diet
Disease control 0.75% adenine
0.75% adenine
0.75% adenine
0.75% adenine
0.75% adenine
0.5% adenine
0.5% adenine
0.5% adenine
0.5% adenine
0.5% adenine
Normal diet
Continuous treatment 1% sevelamer
Continuous treatment 3% sevelamer
Intermittent treatment 1% sevelamer Normal diet
Intermittent treatment Normal diet
Normal diet
Normal diet
2 weeks 2 weeks 2 weeks 2 weeks 2 weeks 2 weeks
Blood sampling day −29
−28
−15
−14
−1 1 3 7 13 15 17 21
14
27 31 35
28
42 45 49
42
56
560Experimental day
3% sevelamer
536 Kidney International (2006) 69, 531–537
o r i g i n a l a r t i c l e N Nagano et al.: Control of PTH and FGF23 by phosphorus
two groups, which were matched with respect to body weight on day
28. The normal control group of nine animals continued to be fed
a normal diet throughout the study. The other group was fed a
normal powder diet containing 0.75% adenine for 2 weeks. Then,
between days 14 and 1, the dietary adenine content was reduced
to 0.5% in this group to avoid death due to severe uremia.
After 4 weeks, the adenine-treated rats were divided into five
groups, each containing nine animals, which were matched with
respect to body weight, BUN, serum creatinine, phosphorus, PTH,
and FGF23 levels on day 1. On day 0, the disease control group
was switched to the normal diet, the continuous-treatment groups
to diet containing 1 or 3% sevelamer for a further 8 weeks and the
intermittent-treatment groups to a diet containing 1 or 3%
sevelamer for 2-week periods, alternating with normal diet, over
the 8-week period (Table 1).
Body weight and food intake volume were measured weekly, and
blood samples were collected on days 1, 3, 7, 13, 15, 17, 21, 27, 31,
35, 42, 45, 49, and 56 in order to measure changes in the serum
parameters over time. All of the animals were killed by abdominal
aortic puncture under ether anesthesia on day 56.
Serum chemistry
Serum phosphorus, calcium and BUN levels were measured using
commercial kits (Wako Pure Chemical Industries, Osaka, Japan).
Serum creatinine was measured using an enzymatic assay (CRE-EN;
Kainos Laboratories, Tokyo, Japan). Serum PTH and 1,25(OH)2D3
were measured using a rat PTH IRMA kit (Immutopics, CA, USA)
and a 1,25(OH)2D RIA kit (TFB; Immunodiagnostic System Ltd,
UK), respectively. Serum FGF23 levels were determined using an
FGF23 ELISA Kit (Kainos Laboratories), which we established
originally for the detection of biologically active intact human
FGF23, using two different monoclonal antibodies specific for the
N- and C-terminals of the molecule.26 This enzyme-linked
immunosorbent assay also detects rodent FGF23.26 All of the serum
parameters, except PTH, and 1,25(OH)2D3, were determined by
a standard calorimetric method using a microplate spectro-
photometer (SpectraMax 250, Molecular Devices, CA, USA).
Drugs
Sevelamer hydrochloride (which is the active ingredient of
Renagels) was synthesized by Dow Chemical Company (Midland,
MI, USA) and supplied via Chugai Pharmaceuticals Co. Ltd (Tokyo,
Japan). Adenine was obtained from Sigma Chemical Co. (St Louis,
MO, USA).
Statistical analysis
All values were expressed as the mean7s.e.m. The data obtained
from the normal control group and the disease control group were
compared using the Student’s t-test. Multiple comparisons were
performed among the five adenine-treated groups using the
parametric Dunnett’s test. Statistical significance was defined as
Po0.05, two-sided.
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